Pain management最新文献

{"title":"Transforaminal epidural steroid injection for radiculopathy and the evolution to surgical treatment: a pragmatic prospective observational multicenter study.","authors":"Vincent Raymaekers, Gert Roosen, Eric Put, Steven Vanvolsem, Salah-Eddine Achahbar, Sacha Meeuws, Maarten Wissels, Sven Bamps, Dirk De Ridder, Tomas Menovsky, Mark Plazier","doi":"10.2217/pmt-2023-0121","DOIUrl":"10.2217/pmt-2023-0121","url":null,"abstract":"<p><p><b>Aim:</b> The aim of this study is to analyze the real-world outcomes of transforaminal epidural steroid injections (TFESIs) in all patients with radiculopathy and their long-term outcomes. <b>Methods:</b> Patients with radiculopathy and failure of conservative treatment were included in a prospective, multicenter, observational cohort study. <b>Results:</b> In total, 117 patients were treated with one or two TFESIs. The mean duration of follow-up was 116 (±14) weeks. In total 19,6% (95% CI: 12.9-28.0%) patients were treated with surgery after insufficient symptom improvement. The evolution to surgery was not associated with etiology, symptom duration or previous spine surgery. <b>Conclusion:</b> Real-world data confirms that TFESIs is an effective treatment with satisfactory results in about 80% of patients for a period of 2 years.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence and pain management: cautiously optimistic.","authors":"Bhargav Srinivasan, Archana Venkataraman, Srinivasa N Raja","doi":"10.1080/17581869.2024.2392483","DOIUrl":"10.1080/17581869.2024.2392483","url":null,"abstract":"","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidevice spinal cord stimulation trials: shared decision making in the era of multiple neuromodulation paradigms.","authors":"Soun Sheen, John Markman, Michael Sohn, Anuj Bhatia, Ram Haddas, Paul Geha, Jennifer Gewandter","doi":"10.1080/17581869.2024.2401767","DOIUrl":"10.1080/17581869.2024.2401767","url":null,"abstract":"<p><p><b>Aim:</b> There is a lack of evidence-based standards for matching spinal cord stimulation (SCS) paradigm to individual patients. We aim to determine the feasibility and safety of a new alternative trial strategy, a sequential multidevice trial.<b>Materials & methods:</b> A retrospective analysis was performed on 116 patients who underwent SCS trials, single device or sequential multidevice (tonic and high-frequency), for chronic low back pain to assess feasibility and compare trial-to-implantation rate and explantation rate.<b>Results:</b> Multidevice SCS trials are feasible and safe. There was no statistically significant difference in the trial-to-implantation and explantation rates between the two groups.<b>Conclusion:</b> Multidevice SCS trial, prioritizing patient preference, may serve as an alternative trial strategy to improve long-term success of SCS.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.","authors":"Shambo Samrat Samajdar, Gaurab Bhaduri, Pradip Kumar Ghoshal, Shatavisa Mukherjee, Jyotirmoy Pal, Nandini Chatterjee, Shashank R Joshi","doi":"10.1080/17581869.2024.2402214","DOIUrl":"10.1080/17581869.2024.2402214","url":null,"abstract":"<p><p><b>Aim:</b> This study aims to evaluate the dual benefits of dulaglutide in improving glycemic control and reducing knee OA pain.<b>Patients & methods:</b> Elderly T2DM patients diagnosed with bilateral knee OA on conventional OA treatment for at least 3 months were studied for their glycemic metrics, OA pain scores and NSAID consumption at baseline, 3 months and 6 months.<b>Results:</b> Significant improvements in glycemic control were observed, HbA1c decreased from 8.7% to 6.5% over 6 months. Pain scores, NSAID, body weight and BMI showed substantial reductions over time. Positive correlation (r = 0.73, <i>p</i> < 0.001) was found between glycemic control and pain reduction.<b>Conclusion:</b> Dulaglutide improves glycemic control, knee joint OA pain and weight management in elderly patients with T2DM.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of naltrexone in the treatment of chronic pain: a systematic review.","authors":"Victor Rassi-Mariani, Eduardo Silva Reis Barreto, César Romero Antunes, Vinicius Borges Alencar, Liliane Elze Falcão Lins-Kusterer, Liana Maria Torres de Araujo Azi, Durval Campos Kraychete","doi":"10.1080/17581869.2024.2401769","DOIUrl":"10.1080/17581869.2024.2401769","url":null,"abstract":"<p><p>This study aims to assess the efficacy of low-dose naltrexone (LDN) in treating chronic pain. We conducted a systematic review using the PICO strategy: (P) Patients with chronic pain, (I) Use of oral naltrexone, (C) Placebo or active drug and (O) Pain relief and quality of life. We included articles from PubMed, Scopus, Cochrane CENTRAL and EMBASE databases. Seven randomized clinical trials involving 406 patients were analyzed. The doses ranging from 2 to 4.5 mg once daily across all studies. Various chronic pain conditions were evaluated. The results suggest that low-dose naltrexone is not effective in managing chronic pain and improving the quality of life in patients with diverse chronic pain conditions. However, further research with larger sample sizes and standardized methodologies is necessary.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hip and waist circumference correlations with demographic factors and pain intensity in patients with chronic pain.","authors":"Frank A Trujillo, Hannah A Thomas, Deepak Berwal, Nikhil Rajulapati, Marisa DiMarzio, Julie G Pilitsis","doi":"10.1080/17581869.2024.2403961","DOIUrl":"10.1080/17581869.2024.2403961","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to investigate how demographic factors such as race, age, sex and ethnicity can impact hip circumference (HC) and waist circumference (WC) in patients with chronic pain.<b>Materials & methods:</b> We queried the NIH-sponsored All of Us database for patients with documented HC, WC and waist/hip ratio (WHR) data. This cross-sectional study categorized participants into four groups: total cohort, no chronic pain, mild/moderate chronic pain (numeric rating scale < 7) and severe chronic pain (numeric rating scale > 7). Further subgroup analyses were performed based on race, age, sex and ethnicity. We examined the correlation between chronic pain and WC, HC and WHR. ANCOVA analysis was used to determine to investigate demographics.<b>Results:</b> This study included 204,013 participants, with 25.22% having a chronic pain diagnoses. In most subgroups, females had significantly greater HC, while males had greater WC and WHR. WC (<i>p</i> < 0.001 in females, <i>p</i> < 0.01 in males), HC (<i>p</i> < 0.001 in females) and WHR (<i>p</i> < 0.001 in females, <i>p</i> < 0.05 in males) were significantly greater in the severe pain group compared with the mild/moderate pain group.<b>Conclusion:</b> These findings suggest that when assessing HC and WC, demographic variables need to be considered to develop more personalized and comprehensive treatment plans for chronic pain patients.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative N-acetylcysteine: evidence and indications.","authors":"Phillip Ryan Wilson, Kathryn H Bridges, Michael Scofield, Sylvia H Wilson","doi":"10.1080/17581869.2024.2388504","DOIUrl":"10.1080/17581869.2024.2388504","url":null,"abstract":"<p><p>Nonopioid analgesics serve to improve analgesia and limit side effects and risks of perioperative opioids. N-acetylcysteine (NAC), the primary treatment of acetaminophen toxicity, may have perioperative indications, including analgesia. NAC impacts glutathione synthesis, oxidant scavenging, glutamate receptor modulation and neuroinflammation. Potential perioperative benefits include arrhythmia prevention after cardiac surgery, decreased contrast-induced nephropathy, improved post-transplant liver function and superior pulmonary outcomes with general anesthesia. NAC may improve perioperative analgesia, with some studies displaying a reduction in postoperative opioid use. NAC is generally well tolerated with an established safety profile. NAC administration may predispose to gastrointestinal effects, while parenteral administration may carry a risk of anaphylactoid reactions, including bronchospasm. Larger randomized trials may clarify the impact of NAC on perioperative analgesic outcomes.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-based survey of Americans with frequent migraine and acute medication use: A plain language summary.","authors":"Amaal J Starling, Roger Cady, Dawn C Buse, Meghan Buzby, Kevin Lenaburg","doi":"10.1080/17581869.2024.2392466","DOIUrl":"10.1080/17581869.2024.2392466","url":null,"abstract":"<p><strong>What is this summary about?: </strong>The Harris Poll Migraine Report Card was a survey about people's experiences and challenges with headaches and migraine. The survey was conducted from December 9, 2021, to January 10, 2022, in the United States. The people who took the survey had frequent headaches/migraine attacks (on 8 or more days per month) and used acute headache/migraine medication to relieve head pain and other symptoms (on 10 or more days per month). This summary focuses on the responses of adults with frequent headaches and frequent acute medication use at the time of the survey or within the few months (not specified) before the survey (and not those who previously had frequent headaches and frequent acute medication use at some point in their life prior to the survey). The group of people who took the survey will be called 'respondents'. The term 'headaches' can mean any type of headache including as part of a migraine attack, a tension type headache, or another unknown headache type. All respondents screened positive for having migraine, so many of the headaches they reported on may have been a migraine headache or part of a migraine attack.</p><p><strong>What were the results?: </strong>Over 50% of respondents said their headaches affected their overall quality of life. Many respondents wished their healthcare provider who was managing their headaches understood more about how headaches affect their mental well-being, how much pain their headaches cause, and why they get headaches. 80% of respondents had concerns about their overall health. Over 60% of respondents said they have experienced anxiety and/or depression. In this survey, although all respondents were eligible to receive a preventive headache/migraine medication because of their headache frequency, only 15% were taking one.</p><p><strong>What do the results of the survey mean?: </strong>The findings from this survey showed many ways that headaches/migraine care can improve, including talking about mental and emotional well-being, making sure the treatment plan works and does not have side effects that cannot be tolerated, and trying to prevent headaches/migraine from occurring.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IonicRF™: a novel step in technology for radiofrequency ablation treatments.","authors":"Harjot S Bhandal, Chau Vu, Jason E Pope","doi":"10.2217/pmt-2021-0068","DOIUrl":"10.2217/pmt-2021-0068","url":null,"abstract":"<p><p>Radiofrequency ablation (RFA) has been utilized since the 1970s to treat various painful conditions. The technology has evolved from its initial use to treat lumbar facet mediated pain with monopolar lesioning to now treat a plethora of chronic pain conditions. This article reviews Abbott Corporation's (IL, USA) IonicRF™ generator. The IonicRF generator utilizes an intelligent power algorithm that improves efficiency and reduces procedure time. The generator also carries a wide range of RFA therapies such as monopolar, bipolar, pulsed or pulsed dose radiofrequency. Additionally, the IonicRF RFA generator is compatible with the Simplicity™ RF probe (Abbott) which allows for efficient and effective denervation of the sacroiliac joint.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39676018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch.","authors":"Filip Stanicic, Dimitrije Grbic, Djurdja Vukicevic, Vladimir Zah","doi":"10.2217/pmt-2023-0124","DOIUrl":"10.2217/pmt-2023-0124","url":null,"abstract":"<p><p><b>Aims:</b> Retrospective insurance claims analysis exploring treatment characteristics in chronic low back pain patients prescribed buprenorphine buccal film (Belbuca^®) or transdermal patches. <b>Patients and methods:</b> The first buprenorphine prescription (buccal film or transdermal patch) was an index event. Patients were observed over 6 month pre- and post-index periods. Propensity score matching minimized the selection bias. <b>Results:</b> Buccal film patients had a higher buprenorphine daily dose (501.7 vs 270.9 µg; p < 0.001). The patch-to-film switching rate was higher than vice versa (11.5 vs 3.8%; p < 0.001). The buccal film showed a greater reduction in opioid prescriptions (-1.1 vs -0.7; p = 0.012), daily morphine milligram equivalents (-12.6 vs -7.3; p < 0.001) and opioid treatment duration (-13.4 vs -7.6 days; p = 0.022). <b>Conclusion:</b> Buccal film was associated with higher buprenorphine doses and a greater reduction of opioid burden.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139485647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}